Charleston Area Medical Center (CAMC) has documented reduced readmissions for congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) and other chronic conditions. Driving this success is a comprehensive strategy supported by the SmarTigr interactive patient engagement and education system from TeleHealth Services.
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a study of the IN.PACT Admiral drug-coated balloon (DCB) for a potential new indication in patients with end-stage renal disease. The randomized study will evaluate the IN.PACT Admiral DCB as a treatment for failing arteriovenous (AV) fistulas in these patients as compared to plain balloon angioplasty. The IDE approval enables Medtronic to initiate the study and gain safety and effectiveness data for the device in this investigational indication.
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a presentation at the 29th International Symposium on Endovascular Therapy (ISET), Feb. 4-8 in Hollywood, Fla. The study is evaluating the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in treating patients with symptomatic lower extremity peripheral artery disease (PAD).
A new anticancer agent in development promotes regeneration of damaged heart muscle — an unexpected research finding that may help prevent congestive heart failure in the future.
GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan (regadenoson) in territories outside the U.S., Canada and Mexico. GE Healthcare will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.
Healthcare analytics company Innovaccer Inc. announced the launch of its holistic MIPS Platform designed to enable providers to deliver better clinical outcomes. The platform does this by helping providers monitor performances, understand population, efficiently manage data and easily submit it to the Centers for Medicare and Medicaid Services (CMS).
